IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
2
Neutral
8
Bullish
4
Bearish
26
Neutral
16
Bullish
4
Bearish
24
Neutral
8
Bullish
0
Bearish
24
Neutral
8
Bullish
0
Bearish
24
Neutral
8
Bullish
0
Bearish
24
Neutral
8
Bullish
0
Upcoming Result Date: Nov 13, 2026
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Vanta Bioscience Ltd (VANTABIO) is currently trading at 19.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Vanta Bioscience Limited is a full‑service preclinical contract research organization providing GLP toxicology, in vitro and in vivo safety assessments and preclinical proof‑of‑concept studies to pharmaceutical, medical device, nutraceutical, agrochemical, cosmetic and chemical clients across India and internationally. Financially the company reported a weak half year operational outcome: consolidated revenue from operations fell to Rs. 30.18 lacs in H1 FY2026 from Rs. 107.03 lacs a year earlier, while consolidated comprehensive loss narrowed modestly to Rs. 181.89 lacs for the period, reflecting continued operating losses and pressure on margins. The balance sheet shows strategic asset build‑out: consolidated other intangible assets total Rs. 3,153.71 lacs with Rs. 1,346.61 lacs under development, property, plant and equipment increased and consolidated borrowings remain elevated (non‑current Rs. 2,300.76 lacs, current Rs. 756.43 lacs), indicating funded capex and leverage to support expansion. Operationally Vanta maintains a GLP‑compliant toxicology platform and an acquired preclinical facility in Gummidipundi, Chennai; the company also operates subsidiaries including Vanta Clinical Research Limited and historically Vayam Research Solutions, positioning it to offer integrated preclinical and clinical research services.
Over the past 52 weeks, Vanta Bioscience Ltd has traded between a low of ₹14.71 and a high of ₹25.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Vanta Bioscience Ltd has a market capitalization of approximately 14.12. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Vanta Bioscience Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 128.36 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 14.12 Cr, Vanta Bioscience Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Vanta Bioscience Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Vanta Bioscience Ltd is 128.36. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Vanta Bioscience Limited is a full‑service preclinical contract research organization providing GLP toxicology, in vitro and in vivo safety assessments and preclinical proof‑of‑concept studies to pharmaceutical, medical device, nutraceutical, agrochemical, cosmetic and chemical clients across India and internationally.
Financially the company reported a weak half year operational outcome: consolidated revenue from operations fell to Rs. 30.18 lacs in H1 FY2026 from Rs. 107.03 lacs a year earlier, while consolidated comprehensive loss narrowed modestly to Rs. 181.89 lacs for the period, reflecting continued operating losses and pressure on margins.
The balance sheet shows strategic asset build‑out: consolidated other intangible assets total Rs. 3,153.71 lacs with Rs. 1,346.61 lacs under development, property, plant and equipment increased and consolidated borrowings remain elevated (non‑current Rs. 2,300.76 lacs, current Rs. 756.43 lacs), indicating funded capex and leverage to support expansion.
Operationally Vanta maintains a GLP‑compliant toxicology platform and an acquired preclinical facility in Gummidipundi, Chennai; the company also operates subsidiaries including Vanta Clinical Research Limited and historically Vayam Research Solutions, positioning it to offer integrated preclinical and clinical research services.
Healthcare Services
Healthcare Research, Analytics & Technology
14 Cr
High Risk
128.4
59.5
-1.3
0.7
25.85
14.71
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
67.02 | 191 Cr | -74.83 | 2.90 | 0.00 | 5.50 | 6.70 | 3.92 | ||
88.71 | 178 Cr | 22.24 | 2.32 | 0.00 | 1.60 | 4.43 | 4.80 | ||
75.31 | 177 Cr | 16.00 | 0.99 | 0.00 | 20.48 | 11.55 | 2.06 | ||
32.67 | 112 Cr | 24.10 | 1.87 | 0.00 | 7.75 | 8.97 | 6.14 | ||
17.00 | 25 Cr | 19.47 | 0.64 | 0.00 | 3.30 | 5.52 | 2.51 | ||
19.85 | 14 Cr | 128.36 | 0.67 | 0.00 | 0.51 | 1.31 | 0.17 | ||
21.20 | 7 Cr | -41.62 | 0.81 | 0.00 | -1.64 | 6.89 | -0.48 | ||
| Median: 7 Co. | — | 32.67 | 112 Cr | 19.47 | 0.99 | 0.00 | 3.30 | 6.70 | 2.51 |
